Antiproteinuric effects of angiotensin receptor blockers: Telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy

Nephrology Dialysis Transplantation

Volumn 23, Issue 10, 2008, Pages 3174-3183

  Galle, Jan ^a,d   Schwedhelm, Edzard ^b   Pinnetti, Sabine ^c   Böger, Rainer H ^b   Wanner, Christoph ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d Clinic of Cardiology and Angiology Klinikum Lüdenscheid   (Germany)

Author keywords

Angiotensin receptor blockers; Diabetic nephropathy; Proteinuria; Telmisartan; Valsartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; N(G),N(G) DIMETHYLARGININE; ORAL ANTIDIABETIC AGENT; STATIN; TELMISARTAN; VALSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DIABETIC NEPHROPATHY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPERTENSION; INFECTION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; METABOLIC DISORDER; MONOTHERAPY; MULTICENTER STUDY; NEOPLASM; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RESPIRATORY TRACT DISEASE; SIDE EFFECT; STROKE; THORAX DISEASE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; URINARY TRACT DISEASE; VASCULAR DISEASE;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ARGININE; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DINOPROST; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; VALINE;

EID: 52649110647     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn230     Document Type: Article

References (45)

1. Russo LM, Osicka TM, Bonnet F et al. Albuminuria in hypertension is linked to altered lysosomal activity and TGF-beta1 expression. Hypertension 2002; 39: 281-286
2. American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004; 27: S79-S83
3. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000: 36: 646-661
4. Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens 2005; 14: 125-131
5. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1-S290
6. Parving HH, Lehnert H, Bröchner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
7. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure independent effect. Circulation 2002; 106: 672-678
8. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
9. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
10. Singh U, Tabibian J, Venugopal SK et al. Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents. Clin Chem 2005; 51: 2252-2256
11. Ferratio CM, Strawn WB. Role of the renin-angiotenin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98: 121-128
12. Ibsen H, Olsen MH, Wachtell K et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 2006; 29: 595-600
13. Böger RH. Asymmetric dimethylarginine (ADMS): a novel risk marker in cardiovascular edicine and beyond. Ann Med 2006; 38: 126-136
14. Böger RH, Bode-Böger SM, Szuba A et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847
15. Ridker PM. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 2004; 148(1 Suppl): S19-S26
16. Davi G, Ciabattoni G, Consoli A et al. In vivo formation of 8-isoprostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-229
17. Feillet-Coudray C, Chone F, Michel F et al. Divergence in plasmatic and urinary isoprostane levels in type 2 diabetes. Clin Chim Acta 2002; 324: 25-30
18. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461-470
19. Pfützner A, Forst T. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 2006; 8: 28-36
20. Schulze F, Wesemann R, Schwedhelm E et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004; 42: 1377-1383
21. Schwedhelm E, Bartling A, Lenzen H et al. Urinary 8-isoprostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004; 109: 843-848
22. de Zeeuw D, Remuzzi G, Parving H-H et al. Albuminuria a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004: 110; 921-927
23. Shoker A, Hossain MA, Koru-Sengul T et al. Performance of creatinine clearance equations on the original Cockcroft-Gault population. Clin Nephrol 2006; 66: 89-97
24. Makino H, Haneda M, Babazono T et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30: 1577-1578
25. Hollenberg NK, Parving HH, Viberti G et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921-1926
26. Onozato ML, Tojo A, Goto A et al. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002; 61: 186-194
27. Persson F, Rossing P, Hovind P et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes 2006; 55: 3550-3555
28. Heitzer T, Schlinzig T, Krohn K et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patient with coronary artery disease. Circulation 2001; 104: 2673-2678
29. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001; 22: 36-52
30. Tarnow L, Hovind P, Teerlink T, et al. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004; 27: 765-769
31. Zoccali C, Bode-Böger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117
32. Schulze F, Maas R, Freese R et al. Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest 2005; 35: 622-626
33. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103: 904-912
34. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses 2004; 62: 499-506
35. Ridker PM, Danielson E, Rifai N et al. Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006; 48: 73-79
36. Fliser D, Buchholz K, Haller H. EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-1107
37. American Diabetes Association. Standards ofmedical care in diabetes. Diabetes Care 2005; 28(Suppl 1): S4-S36
38. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206-1252
39. White WB, Lacourcière Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004; 17: 347-453
40. Lacourcière Y, Krzesinski JM, White WB et al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004; 9: 203-210
41. Weinberg AJ, Zappe AJ, Ashton M et al. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol 2004; 24: 340-345
42. Rossing K, Jacobsen P, Pietraszek L et al. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003; 26: 2268-2274
43. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444
44. Sengul AM, Altuntas Y, Kurkku A et al. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Res Clin Pract 2006; 71: 210-219
45. Teo K, Yusuf S, Sleight P et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148: 52-61